Phase II Trial of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With a Dose-Finding Lead-In

Trial Profile

Phase II Trial of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With a Dose-Finding Lead-In

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Sonidegib (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Dec 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 27 Aug 2015 Planned End Date changed from 1 Oct 2019 to 1 Sep 2020 as reported by ClinicalTrials.gov record.
    • 27 Aug 2015 Planned primary completion date changed from 1 Oct 2018 to 1 Sep 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top